Crossmark Global Holdings Inc. lessened its stake in shares of Amdocs Limited (NASDAQ:DOX - Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 142,216 shares of the technology company's stock after selling 3,340 shares during the period. Crossmark Global Holdings Inc. owned 0.13% of Amdocs worth $12,108,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. First Horizon Advisors Inc. raised its position in Amdocs by 1.9% in the third quarter. First Horizon Advisors Inc. now owns 5,902 shares of the technology company's stock worth $516,000 after acquiring an additional 109 shares during the period. Private Trust Co. NA increased its stake in shares of Amdocs by 62.9% during the 3rd quarter. Private Trust Co. NA now owns 303 shares of the technology company's stock worth $27,000 after purchasing an additional 117 shares during the last quarter. Morton Community Bank raised its holdings in shares of Amdocs by 0.4% in the 3rd quarter. Morton Community Bank now owns 36,410 shares of the technology company's stock worth $3,185,000 after purchasing an additional 130 shares during the period. Private Advisor Group LLC lifted its stake in Amdocs by 3.2% in the third quarter. Private Advisor Group LLC now owns 5,626 shares of the technology company's stock valued at $492,000 after purchasing an additional 175 shares during the last quarter. Finally, First Trust Direct Indexing L.P. grew its holdings in Amdocs by 7.0% during the third quarter. First Trust Direct Indexing L.P. now owns 3,063 shares of the technology company's stock valued at $268,000 after purchasing an additional 200 shares during the period. 92.02% of the stock is owned by institutional investors.
Analyst Ratings Changes
DOX has been the topic of several research reports. Stifel Nicolaus started coverage on Amdocs in a research note on Wednesday, October 2nd. They issued a "buy" rating and a $100.00 target price on the stock. Barclays lowered their price objective on Amdocs from $113.00 to $111.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Oppenheimer increased their target price on shares of Amdocs from $98.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Finally, StockNews.com lowered shares of Amdocs from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Amdocs currently has an average rating of "Moderate Buy" and an average price target of $101.20.
Get Our Latest Analysis on Amdocs
Amdocs Price Performance
NASDAQ DOX traded up $0.81 during trading hours on Tuesday, hitting $85.70. The company had a trading volume of 798,777 shares, compared to its average volume of 520,765. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.20 and a current ratio of 1.20. The firm has a market capitalization of $9.67 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 1.42 and a beta of 0.71. Amdocs Limited has a 52 week low of $74.41 and a 52 week high of $94.04. The firm has a 50 day simple moving average of $85.87 and a 200 day simple moving average of $85.96.
Amdocs Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.479 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $1.92 annualized dividend and a yield of 2.24%. Amdocs's dividend payout ratio is currently 45.28%.
Amdocs Profile
(
Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Featured Articles
Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
